HK1160766A1 - Combination of aurora kinase inhibitors and anti-cd20 antibodies cd20 - Google Patents
Combination of aurora kinase inhibitors and anti-cd20 antibodies cd20Info
- Publication number
- HK1160766A1 HK1160766A1 HK12101147.6A HK12101147A HK1160766A1 HK 1160766 A1 HK1160766 A1 HK 1160766A1 HK 12101147 A HK12101147 A HK 12101147A HK 1160766 A1 HK1160766 A1 HK 1160766A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- antibodies
- combination
- kinase inhibitors
- aurora kinase
- aurora
- Prior art date
Links
- 239000003719 aurora kinase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20350908P | 2008-12-22 | 2008-12-22 | |
PCT/US2009/006560 WO2010074724A1 (en) | 2008-12-22 | 2009-12-15 | Combination of aurora kinase inhibitors and anti-cd20 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1160766A1 true HK1160766A1 (en) | 2012-08-17 |
Family
ID=41664630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK12101147.6A HK1160766A1 (en) | 2008-12-22 | 2012-02-07 | Combination of aurora kinase inhibitors and anti-cd20 antibodies cd20 |
Country Status (13)
Country | Link |
---|---|
US (3) | US20100183601A1 (de) |
EP (1) | EP2376082B1 (de) |
JP (1) | JP5738196B2 (de) |
KR (1) | KR101741168B1 (de) |
CN (1) | CN102264368B (de) |
AU (1) | AU2009330727B2 (de) |
BR (1) | BRPI0923579A2 (de) |
CA (1) | CA2747326C (de) |
ES (1) | ES2468391T3 (de) |
HK (1) | HK1160766A1 (de) |
MX (1) | MX2011006725A (de) |
RU (1) | RU2535032C2 (de) |
WO (1) | WO2010074724A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2535032C2 (ru) | 2008-12-22 | 2014-12-10 | Милленниум Фармасьютикалз, Инк. | Сочетание ингибиторов аврора киназы и анти-cd 20 антител |
JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
WO2011103089A1 (en) | 2010-02-19 | 2011-08-25 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate |
CA2907726A1 (en) * | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase |
JP6525474B2 (ja) * | 2013-12-06 | 2019-06-05 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | オーロラキナーゼ阻害剤と抗cd30抗体の併用 |
AU2017370942A1 (en) | 2016-12-07 | 2019-06-13 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
EP4309722A2 (de) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Einnehmbare vorrichtung zur abgabe eines therapeutischen mittels an den magen-darm-trakt |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4099012A (en) | 1975-08-28 | 1978-07-04 | Ciba-Geigy Corporation | 2-pyrazolyl-benzophenones |
IL59316A (en) | 1979-02-07 | 1983-07-31 | Sparamedica Ag | Phenylpyrimidobenzazepine derivatives,their preparation and pharmaceutical compositions containing them |
US4481142A (en) | 1979-02-07 | 1984-11-06 | Hoffmann-La Roche Inc. | Pyrimido-2-benzazepines |
US4469633A (en) | 1980-05-16 | 1984-09-04 | Hoffmann-La Roche Inc. | N-oxides of 5-oxo-1-phenyl-2-benzazepines |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0273697A3 (de) | 1986-12-30 | 1989-11-29 | Merck & Co. Inc. | 2-Benzazepine mit 5- und 6-gliedrigen heterozyklischen Ringen |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5166151A (en) | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
US5210082A (en) | 1991-05-16 | 1993-05-11 | Merck & Co., Inc. | 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5747487A (en) * | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
EP0888350A1 (de) | 1996-03-08 | 1999-01-07 | Zeneca Limited | Azolobenzazepinderivate als neurologisch aktive mittel |
AU5330698A (en) | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
GB9713087D0 (en) | 1997-06-20 | 1997-08-27 | Celltech Therapeutics Ltd | Chemical compounds |
DE69811930T2 (de) | 1997-09-29 | 2003-12-18 | Meiji Seika Kaisha | Tricyclische triazolobenzazepinderivate, verfahren zu ihrer herstellung und antiallergische mittel |
US6277844B1 (en) | 1998-09-14 | 2001-08-21 | Sydney Spector | Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis |
US6417207B1 (en) | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
CA2378646A1 (en) | 1999-08-11 | 2001-02-15 | Idec Pharmaceuticals Corporation | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
CN1407901A (zh) * | 1999-11-08 | 2003-04-02 | Idec药物公司 | 使用抗cd40l抗体并联合抗cd20抗体和/或化疗剂和放疗治疗b细胞恶性瘤 |
WO2001052353A2 (en) * | 2000-01-12 | 2001-07-19 | Emag Technologies L.L.C. | Low cost compact omni-directional printed antenna |
MXPA02010507A (es) * | 2000-04-25 | 2003-05-14 | Idec Pharma Corp | Administracion intratecal de rituximab para el tratamiento de linfomas del sistema nervioso central. |
US6653300B2 (en) | 2000-12-21 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
HUP0401107A3 (en) | 2001-08-09 | 2004-10-28 | Actelion Pharmaceuticals Ltd | Novel benzo-fused heterocycles, their use process for their preparation and pharmaceutical compositions containing them |
MY141867A (en) | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
PT1578755E (pt) | 2002-12-24 | 2007-10-19 | Astrazeneca Ab | Derivados de fosfonooxiquinazolina e sua utilização farmacêutica |
BRPI0407544A (pt) | 2003-02-17 | 2006-02-14 | Pharmacia Italia Spa | derivados de pirazol tetracìclicos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas que os compreendem |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
GB0315657D0 (en) | 2003-07-03 | 2003-08-13 | Astex Technology Ltd | Pharmaceutical compounds |
US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
US20050025605A1 (en) * | 2003-07-30 | 2005-02-03 | Vrana John J. | Locator stud and method of assembly |
US20050113398A1 (en) | 2003-08-07 | 2005-05-26 | Ankush Argade | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
DK1771450T5 (da) * | 2004-05-14 | 2012-01-09 | Millennium Pharm Inc | Forbindelser og fremgangsmåder til inhibering af mitotisk progression ved inhibering af AURORA-kinase |
US7754714B2 (en) | 2004-05-18 | 2010-07-13 | Rigel Pharmaceuticals, Inc. | Cycloalkyl substituted pyrimidinediamine compounds and their uses |
JP2008505167A (ja) | 2004-07-05 | 2008-02-21 | アステックス、セラピューティックス、リミテッド | 医薬組成物 |
EP1768984B1 (de) | 2004-07-16 | 2010-10-20 | Sunesis Pharmaceuticals, Inc. | Als aurora-kinase-inhibitoren nutzbare thienopyrimidine |
GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
ES2320364T3 (es) | 2004-11-15 | 2009-05-21 | Rigel Pharmaceuticals, Inc. | Procedimiento de preparacion de beta-lactamas protegidas por n-carbamato opticamente activo por resolucion optica por medio de una lipasa de candida antarctica. |
JP2008520713A (ja) | 2004-11-17 | 2008-06-19 | ミイカナ セラピューティクス インコーポレイテッド | キナーゼ阻害剤 |
US20100160324A1 (en) | 2004-12-30 | 2010-06-24 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
US20080312223A1 (en) | 2004-12-30 | 2008-12-18 | Astex Therapeutics Limited | Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases |
US8110573B2 (en) | 2004-12-30 | 2012-02-07 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
WO2006070202A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Pyrazole derivatives having kinase modulating activity |
US7485661B2 (en) | 2005-01-18 | 2009-02-03 | Pfizer Italia S.R.L. | Heterobicyclic pyrazole derivatives as kinase inhibitors |
US20070104785A1 (en) * | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
KR20140025610A (ko) | 2005-09-30 | 2014-03-04 | 미카나 테라퓨틱스, 인크. | 치환된 피라졸 화합물 |
AR056764A1 (es) | 2005-11-03 | 2007-10-24 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de quinasa |
EP1962830B1 (de) * | 2005-12-23 | 2013-03-27 | GlaxoSmithKline LLC | Azaindol-hemmer von aurora-kinasen |
CN100346830C (zh) * | 2005-12-28 | 2007-11-07 | 上海交通大学医学院附属瑞金医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
BRPI0708034A2 (pt) * | 2006-02-10 | 2011-05-17 | Transtech Pharma Inc | derivados benzazol, composições e métodos de uso como inibidores aurora quinase |
TW200808311A (en) | 2006-03-30 | 2008-02-16 | Nerviano Medical Sciences Srl | Use of a kinase inhibitor for the treatment of particular resistant tumors |
GB0609530D0 (en) | 2006-05-12 | 2006-06-21 | Cyclacel Ltd | Combination |
WO2007132221A1 (en) | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combined anticancer pyrimidine-thiazole aurora kinase inhibitors |
WO2007132220A1 (en) | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder |
MX2009000132A (es) * | 2006-06-30 | 2009-01-26 | Schering Corp | Metodo para el uso de piperidinas sustituidas que incrementan la actividad de p53. |
US7718648B2 (en) | 2006-08-09 | 2010-05-18 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
US20090023743A1 (en) * | 2007-05-09 | 2009-01-22 | Abbott Laboratories | Inhibitors of protein kinases |
US20090203671A1 (en) | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
US20110033461A1 (en) * | 2008-03-12 | 2011-02-10 | Vladimir Ratushny | Combination Therapy for the Treatment of Cancer |
RU2535032C2 (ru) | 2008-12-22 | 2014-12-10 | Милленниум Фармасьютикалз, Инк. | Сочетание ингибиторов аврора киназы и анти-cd 20 антител |
JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
JO3434B1 (ar) * | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
WO2011057188A1 (en) * | 2009-11-06 | 2011-05-12 | Idexx Laboratories, Inc. | Canine anti-cd20 antibodies |
WO2011103089A1 (en) * | 2010-02-19 | 2011-08-25 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate |
-
2009
- 2009-12-15 RU RU2011130566/15A patent/RU2535032C2/ru active
- 2009-12-15 ES ES09795585.0T patent/ES2468391T3/es active Active
- 2009-12-15 MX MX2011006725A patent/MX2011006725A/es active IP Right Grant
- 2009-12-15 KR KR1020117016859A patent/KR101741168B1/ko active IP Right Grant
- 2009-12-15 CN CN200980152195.9A patent/CN102264368B/zh not_active Expired - Fee Related
- 2009-12-15 WO PCT/US2009/006560 patent/WO2010074724A1/en active Application Filing
- 2009-12-15 AU AU2009330727A patent/AU2009330727B2/en not_active Ceased
- 2009-12-15 JP JP2011542127A patent/JP5738196B2/ja active Active
- 2009-12-15 CA CA2747326A patent/CA2747326C/en not_active Expired - Fee Related
- 2009-12-15 EP EP09795585.0A patent/EP2376082B1/de active Active
- 2009-12-15 US US12/638,018 patent/US20100183601A1/en not_active Abandoned
- 2009-12-15 BR BRPI0923579A patent/BRPI0923579A2/pt not_active Application Discontinuation
-
2012
- 2012-02-07 HK HK12101147.6A patent/HK1160766A1/xx not_active IP Right Cessation
-
2016
- 2016-02-25 US US15/052,966 patent/US20160271249A1/en not_active Abandoned
- 2016-12-22 US US15/387,740 patent/US10391100B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20110114586A (ko) | 2011-10-19 |
RU2535032C2 (ru) | 2014-12-10 |
CN102264368A (zh) | 2011-11-30 |
US10391100B2 (en) | 2019-08-27 |
BRPI0923579A2 (pt) | 2020-01-14 |
ES2468391T3 (es) | 2014-06-16 |
JP5738196B2 (ja) | 2015-06-17 |
AU2009330727A1 (en) | 2011-07-07 |
CN102264368B (zh) | 2014-09-10 |
MX2011006725A (es) | 2011-09-15 |
KR101741168B1 (ko) | 2017-05-29 |
US20100183601A1 (en) | 2010-07-22 |
US20170296551A1 (en) | 2017-10-19 |
AU2009330727B2 (en) | 2016-07-28 |
JP2012513390A (ja) | 2012-06-14 |
CA2747326C (en) | 2017-05-16 |
RU2011130566A (ru) | 2013-01-27 |
EP2376082B1 (de) | 2014-03-05 |
EP2376082A1 (de) | 2011-10-19 |
US20160271249A1 (en) | 2016-09-22 |
CA2747326A1 (en) | 2010-07-01 |
WO2010074724A1 (en) | 2010-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1160766A1 (en) | Combination of aurora kinase inhibitors and anti-cd20 antibodies cd20 | |
HUS2100008I1 (hu) | Halauxifen-metil és floraszulam kombinációja | |
IL248723B (en) | Specific antibodies against the bcr complex and methods of using them | |
IL198020A0 (en) | Anti-cd20 antibodies and methods of use | |
HK1160119A1 (en) | Kinase inhibitors and methods of use | |
EP2252293A4 (de) | Kinasehemmer und verwendungsverfahren | |
IL216511A0 (en) | Janus kinase inhibitor compounds and methods | |
HK1144306A1 (zh) | 激酶抑制劑及其用途 | |
IL211549A0 (en) | Aminotriazolopyridines and their use as kinase inhibitors | |
HK1172896A1 (zh) | 化合物和使用方法 | |
HK1161094A1 (en) | Compounds and methods of use | |
ZA200906946B (en) | Inhibitors of iap | |
EP2121637A4 (de) | Anthranilamid-hemmer der aurorakinase | |
EP2373691A4 (de) | Anti-fxi-antikörper und verfahren zu ihrer verwendung | |
EP2387572A4 (de) | Proteinkinase-c-hemmer und ihre verwendung | |
IL211623A0 (en) | Anti-notch2 antibodies and methods of use | |
EP2365809A4 (de) | Pyrazinopyrazine und derivate als kinasehemmer | |
DK2358710T3 (da) | AKT- og P70-S6-kinaseinhibitorer | |
IL207415A0 (en) | Protein kinase inhibitors and use thereof | |
ZA201003420B (en) | Protein kinase inhibitors and use thereof | |
EP2242854A4 (de) | Sirna-verbindungen und verfahren zur verwendung davon | |
ZA201106697B (en) | Humanized anti-cd20 antibodies and methods of use | |
EP2379076A4 (de) | Phosphodiesterase-hemmer und ihre verwendungen | |
GB0805693D0 (en) | Combinations of P13-delta and P13-gamma kinase inhibitor compounds | |
IL211752A0 (en) | Antibody combinations and use of same for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20211212 |